Scilex Holding Co. (SCLX)

$17.69 -0.18 (-1.01%)
Market Cap 135.55M
Revenue (ttm) 56.59M
Net Income (ttm) -72.81M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -128.66%
Debt to Equity Ratio -0.16
Volume 63,100
Avg Vol 223,682
Day's Range N/A - N/A
Shares Out 7.59M
Stochastic %K 29%
Beta 1.34
Analysts Hold
Price Target $367.13

Company Profile

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 650 516 4310
Address:
960 San Antonio Road, Palo Alto, United States
KimCoyneFactoryPR
KimCoyneFactoryPR Nov. 15 at 12:27 AM
$SCLX here are the key takeaways from the 3rd Quarter 2025 10-Q: - Less than $1M in cash available - $213M in rebate liabilities (these have to be paid) -$67M in outstanding AP (this is owed to vendors and third parties) - YTD sales revenue down 40% YoY (down 27% in Q3 vs prior Q3) - $258M loss in Q3. A quarter of a billion dollars How do you pay off $213M in rebate liabilities with less than $1M in cash? Explain it, and if you can I will invest in this company.
0 · Reply
GlobalMarketBulletin
GlobalMarketBulletin Nov. 14 at 11:36 PM
$SCLX Scilex Holding Company shares surged 26% in the past month after heavy sell-offs earlier in 2025. Despite the rebound, SCLX remains down 30% year-over-year as investors weigh its declining 13% revenue, 2.5× P/S ratio, and future in non-opioid pain therapy. https://globalmarketbulletin.com/scilex-sclx-jumps-26-in-30-days-but-still-down-30-yoy-is-the-rally-sustainable/
0 · Reply
KingStocks1
KingStocks1 Nov. 14 at 11:18 PM
$SCLX 1 mill comprehensive loss last year this quarter vs this year showing 260 million loss for the quarter ending September 2025??? What the fk!?
0 · Reply
Excitingshorts
Excitingshorts Nov. 14 at 11:04 PM
$SCLX 2025 is the last year of being in the red. Well be positive next quarter due to increased global revenue. Not easy for any biotech to say that
1 · Reply
d_risk
d_risk Nov. 14 at 10:58 PM
$SCLX - Scilex Holding Company Common Stock - 10Q - Updated Risk Factors SCLX’s latest 10-Q flags updated financials, debt, and supplier risks, plus a major new focus on crypto: regulatory uncertainty, market swings, cybersecurity threats, and accounting challenges now loom large. #Pharmaceuticals #Cybersecurity #FinancialRisk #RegulatoryRisk #Cryptocurrency 🟢 Added 🟠 Removed https://d-risk.ai/SCLX/10-Q/2025-11-14
0 · Reply
BioCEOsSukk
BioCEOsSukk Nov. 14 at 10:47 PM
$SCLX $DVLT $SRNE https://ir.geniusgroup.net/news-events/press-releases/detail/214/genius-group-files-federal-securities-class-action-lawsuit
0 · Reply
Rookie69
Rookie69 Nov. 14 at 10:35 PM
$SCLX think the village idiot will ask AI to expain another 40% drop in sales or keep fapping to Kimmys bullshit along with DJ this 10-Q may take the prize as worst Henry performance to date
0 · Reply
BioCEOsSukk
BioCEOsSukk Nov. 14 at 10:26 PM
$SCLX holy filings, Batman. Scilex getting their filings in order for something? 😁😁😁
0 · Reply
Sacsofcash
Sacsofcash Nov. 14 at 8:18 PM
$SCLX KimCoyneFactoryPR 👇👇👇👇👇👇👇
2 · Reply
Argentum99
Argentum99 Nov. 14 at 6:59 PM
$SCLX done. I vote against. Ji, $SCLX SP102 SEMDEXA, in commercial phase, when?? and $SRNE chapter 11 definitions, when??
0 · Reply
Latest News on SCLX
Scilex Holding Company Announces that the Board of Directors of Datavault AI Inc. Has Approved the Distribution of a Dream Bowl 2026 Meme Coin to All Eligible Scilex and Datavault AI Stockholders of Record and Set a Record Date of November 25, 2025

Nov 11, 2025, 9:30 AM EST - 3 days ago

Scilex Holding Company Announces that the Board of Directors of Datavault AI Inc. Has Approved the Distribution of a Dream Bowl 2026 Meme Coin to All Eligible Scilex and Datavault AI Stockholders of Record and Set a Record Date of November 25, 2025

Scilex Holding Company Announces Worldwide Exclusive License for Tokenization and Monetization of Real-World Asset (RWA) in Genomic, DNA Data, Diagnosis, Therapeutics Products, Genetic and Drug information from Datavault AI

Nov 4, 2025, 6:00 AM EST - 10 days ago

Scilex Holding Company Announces Worldwide Exclusive License for Tokenization and Monetization of Real-World Asset (RWA) in Genomic, DNA Data, Diagnosis, Therapeutics Products, Genetic and Drug information from Datavault AI

Scilex Holding Company Announces the Sponsorship of Dream Bowl 2026 and Set a Record Date of November 14, 2025 for Its Shareholders to Receive Dream Bowl 2026 Meme Coin Distributed by DataVault AI

Nov 3, 2025, 9:53 AM EST - 11 days ago

Scilex Holding Company Announces the Sponsorship of Dream Bowl 2026 and Set a Record Date of November 14, 2025 for Its Shareholders to Receive Dream Bowl 2026 Meme Coin Distributed by DataVault AI

Datavault AI Announces Record Date of Nov. 14, 2025, for Dream Bowl Draft Meme Coin Distribution to All Eligible Scilex and Datavault AI Shareholders

Nov 3, 2025, 8:45 AM EST - 11 days ago

Datavault AI Announces Record Date of Nov. 14, 2025, for Dream Bowl Draft Meme Coin Distribution to All Eligible Scilex and Datavault AI Shareholders

DVLT

Scilex Holding Company Announces the Completion of the First Tranche of the Oramed Pharmaceuticals, Inc. Warrant Repurchase

Oct 1, 2025, 9:00 AM EDT - 6 weeks ago

Scilex Holding Company Announces the Completion of the First Tranche of the Oramed Pharmaceuticals, Inc. Warrant Repurchase

Datavault AI Announces Closing of Initial Tranche Investment from Scilex Holding Company

Sep 26, 2025, 4:12 PM EDT - 7 weeks ago

Datavault AI Announces Closing of Initial Tranche Investment from Scilex Holding Company

DVLT

Scilex Holding Company Announces Closing of Previously Announced Initial Tranche Investment in Datavault AI

Sep 26, 2025, 3:57 PM EDT - 7 weeks ago

Scilex Holding Company Announces Closing of Previously Announced Initial Tranche Investment in Datavault AI

Scilex Holding Company Announces $150 Million Strategic Bitcoin Investment in Datavault AI

Sep 25, 2025, 3:45 PM EDT - 7 weeks ago

Scilex Holding Company Announces $150 Million Strategic Bitcoin Investment in Datavault AI

Scilex Announces Closing of Previously Announced Non-Dilutive Value Enhancing Transaction with an Institutional Investor for the Exchange of $200 Million of Common Stock of Semnur Pharmaceuticals, Inc. Held by Scilex Holding Company for $200 Million in Bitcoin

Sep 25, 2025, 6:00 AM EDT - 7 weeks ago

Scilex Announces Closing of Previously Announced Non-Dilutive Value Enhancing Transaction with an Institutional Investor for the Exchange of $200 Million of Common Stock of Semnur Pharmaceuticals, Inc. Held by Scilex Holding Company for $200 Million in Bitcoin

Scilex Holding Company Announces It Has Entered into a Memorandum of Understanding with Biconomy.com to Collaborate on Future Cryptocurrency Strategies and Treasury Management

Sep 24, 2025, 10:11 AM EDT - 7 weeks ago

Scilex Holding Company Announces It Has Entered into a Memorandum of Understanding with Biconomy.com to Collaborate on Future Cryptocurrency Strategies and Treasury Management

Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”) Announces Signing of a Securities Purchase Agreement with an Institutional Investor for the Purchase of $100 Million of shares of Semnur Common Stock in Exchange for $100 Million in Bitcoin

Sep 23, 2025, 11:12 AM EDT - 7 weeks ago

Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”) Announces Signing of a Securities Purchase Agreement with an Institutional Investor for the Purchase of $100 Million of shares of Semnur Common Stock in Exchange for $100 Million in Bitcoin

Scilex Holding Company Announces Signing of a Securities Purchase Agreement with an Institutional Investor to Exchange $200 Million of Common Stock of Semnur Pharmaceuticals, Inc. Held By Scilex Holding Company for $200 Million in Bitcoin

Sep 23, 2025, 10:00 AM EDT - 7 weeks ago

Scilex Holding Company Announces Signing of a Securities Purchase Agreement with an Institutional Investor to Exchange $200 Million of Common Stock of Semnur Pharmaceuticals, Inc. Held By Scilex Holding Company for $200 Million in Bitcoin

Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), and Denali Capital Acquisition Corp. Announced the Closing of Their Previously Announced Business Combination on September 22, 2025

Sep 23, 2025, 6:00 AM EDT - 7 weeks ago

Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), and Denali Capital Acquisition Corp. Announced the Closing of Their Previously Announced Business Combination on September 22, 2025

Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), and Denali Capital Acquisition Corp. Announce the Closing of Their Previously Announced Business Combination

Sep 22, 2025, 3:49 PM EDT - 7 weeks ago

Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), and Denali Capital Acquisition Corp. Announce the Closing of Their Previously Announced Business Combination

Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), and Denali Capital Acquisition Corp. Announce Approval from Denali's Shareholders of the Previously Announced Business Combination

Sep 4, 2025, 9:00 AM EDT - 2 months ago

Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), and Denali Capital Acquisition Corp. Announce Approval from Denali's Shareholders of the Previously Announced Business Combination

Scilex Holding Company (Nasdaq: SCLX) Announces Its Majority-Owned Subsidiary, Semnur Pharmaceuticals, Inc. (“Semnur”), and Denali Capital Acquisition Corp. Have Entered into a Purchase Agreement with an Investor for a $20 Million Private Placement at $16.00 per share and Jaisim Shah, Scilex's CEO and President, Will be Dedicated to Semnur on a Full Time Basis to Rapidly Advance SP-102 to Regulatory Approval and Commercialization for the Treatment of Lumbosacral Radicular Pain (LRP)/Sciatica

Aug 21, 2025, 6:00 AM EDT - 3 months ago

Scilex Holding Company (Nasdaq: SCLX) Announces Its Majority-Owned Subsidiary, Semnur Pharmaceuticals, Inc. (“Semnur”), and Denali Capital Acquisition Corp. Have Entered into a Purchase Agreement with an Investor for a $20 Million Private Placement at $16.00 per share and Jaisim Shah, Scilex's CEO and President, Will be Dedicated to Semnur on a Full Time Basis to Rapidly Advance SP-102 to Regulatory Approval and Commercialization for the Treatment of Lumbosacral Radicular Pain (LRP)/Sciatica

Scilex Holding Company (Nasdaq: SCLX) Announces Effectiveness of Registration Statement on Form S-4 for the Proposed Business Combination of Denali Capital Acquisition Corp. and Semnur Pharmaceuticals, Inc., a Majority-Owned Subsidiary of Scilex

Aug 13, 2025, 6:00 AM EDT - 3 months ago

Scilex Holding Company (Nasdaq: SCLX) Announces Effectiveness of Registration Statement on Form S-4 for the Proposed Business Combination of Denali Capital Acquisition Corp. and Semnur Pharmaceuticals, Inc., a Majority-Owned Subsidiary of Scilex

Scilex Holding Company Announces Deferral of Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from May 2, 2025 to a future date to be determined by the Board

Jun 23, 2025, 4:50 PM EDT - 5 months ago

Scilex Holding Company Announces Deferral of Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from May 2, 2025 to a future date to be determined by the Board

Scilex Holding Company Announces Publication on GLOPERBA® Dosing Adjustments in Peer-Review Journal

Jun 5, 2025, 12:05 PM EDT - 5 months ago

Scilex Holding Company Announces Publication on GLOPERBA® Dosing Adjustments in Peer-Review Journal

Scilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL

May 16, 2025, 9:00 AM EDT - 6 months ago

Scilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL

Scilex Holding Company to Present Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL.

May 1, 2025, 9:00 AM EDT - 7 months ago

Scilex Holding Company to Present Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL.

Scilex Holding Company Regains Compliance with NASDAQ Minimum Bid Price Rule

Apr 30, 2025, 1:46 PM EDT - 7 months ago

Scilex Holding Company Regains Compliance with NASDAQ Minimum Bid Price Rule

Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April 11, 2025 to May 2, 2025

Apr 22, 2025, 9:00 AM EDT - 7 months ago

Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April 11, 2025 to May 2, 2025

Scilex Holding Company Announces FDA Has Approved Our Request for the Orphan Drug Designation for Colchicine for the Treatment of Pericarditis

Apr 16, 2025, 2:12 PM EDT - 7 months ago

Scilex Holding Company Announces FDA Has Approved Our Request for the Orphan Drug Designation for Colchicine for the Treatment of Pericarditis

Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada's Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB®'s Acute Treatment of Migraine With or Without Aura in Canada

Apr 15, 2025, 9:00 AM EDT - 7 months ago

Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada's Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB®'s Acute Treatment of Migraine With or Without Aura in Canada

Scilex Holding Company Announces 1-for-35 Reverse Stock Split

Apr 11, 2025, 9:00 AM EDT - 7 months ago

Scilex Holding Company Announces 1-for-35 Reverse Stock Split

Scilex Holding Company Has Appealed Lower Court Decision to the U.S. Court of Appeals for the Federal Circuit in Washington, DC and Will Continue to Vigorously Pursue its Infringement Action Against Aveva

Mar 26, 2025, 8:24 PM EDT - 8 months ago

Scilex Holding Company Has Appealed Lower Court Decision to the U.S. Court of Appeals for the Federal Circuit in Washington, DC and Will Continue to Vigorously Pursue its Infringement Action Against Aveva

Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from January 28, 2025 to April 11, 2025

Mar 10, 2025, 9:00 AM EDT - 8 months ago

Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from January 28, 2025 to April 11, 2025

Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025

Jan 31, 2025, 9:00 AM EST - 10 months ago

Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025

Scilex Holding Company Announces that It Regains Nasdaq Compliance Under Listing Rule 5250(c)(1)

Jan 21, 2025, 11:49 AM EST - 10 months ago

Scilex Holding Company Announces that It Regains Nasdaq Compliance Under Listing Rule 5250(c)(1)

Scilex Holding Company Announces Extension of the Maturity Date of its Secured Promissory Note Issued to Oramed Pharmaceuticals Inc. to December 31, 2025

Jan 21, 2025, 9:46 AM EST - 10 months ago

Scilex Holding Company Announces Extension of the Maturity Date of its Secured Promissory Note Issued to Oramed Pharmaceuticals Inc. to December 31, 2025

Scilex Holding Company Announces that Its Note Holders Intend to Participate in the Funding and Licensing of Gloperba® Ex-U.S. Commercialization Rights from Romeg Therapeutics, LLC

Jan 21, 2025, 9:00 AM EST - 10 months ago

Scilex Holding Company Announces that Its Note Holders Intend to Participate in the Funding and Licensing of Gloperba® Ex-U.S. Commercialization Rights from Romeg Therapeutics, LLC

Scilex Holding Company Announces Filing of its Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2024

Jan 21, 2025, 6:00 AM EST - 10 months ago

Scilex Holding Company Announces Filing of its Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2024

Scilex Holding Company Amends its License Agreement with Romeg Therapeutics, LLC, For the Worldwide Rights to Commercialize Gloperba®, an FDA-Approved Prophylactic Treatment for Painful Gout Flares in Adults

Jan 16, 2025, 3:38 PM EST - 10 months ago

Scilex Holding Company Amends its License Agreement with Romeg Therapeutics, LLC, For the Worldwide Rights to Commercialize Gloperba®, an FDA-Approved Prophylactic Treatment for Painful Gout Flares in Adults

Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from November 7, 2024 to January 28, 2025

Dec 30, 2024, 9:00 AM EST - 11 months ago

Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from November 7, 2024 to January 28, 2025

Scilex Holding Company Announces Closing of $17 Million Registered Direct Offering

Dec 13, 2024, 12:23 PM EST - 1 year ago

Scilex Holding Company Announces Closing of $17 Million Registered Direct Offering

Scilex Holding Company Announces $17 Million Registered Direct Offering

Dec 12, 2024, 8:21 AM EST - 1 year ago

Scilex Holding Company Announces $17 Million Registered Direct Offering

Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports KDS2010 a Novel Oral Tablet Phase 2 Trial for Alzheimer's Disease (AD) Currently Enrolling with U.S. Patient Cohort to be Added in 2025

Dec 11, 2024, 12:49 PM EST - 1 year ago

Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports KDS2010 a Novel Oral Tablet Phase 2 Trial for Alzheimer's Disease (AD) Currently Enrolling with U.S. Patient Cohort to be Added in 2025

Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports Phase 2 Trial for Obesity Currently Enrolling with U.S. Patient Cohort to be Added in 2025. Scilex Bio Reports Positive Results from the Recently Completed Phase 1 Trials Conducted by NeuroBiogen for KDS2010, a Novel Oral Tablet Recently Synthesized Potent, Selective, and Reversible Monoamine Oxidase B inhibitor

Dec 11, 2024, 7:30 AM EST - 1 year ago

Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports Phase 2 Trial for Obesity Currently Enrolling with U.S. Patient Cohort to be Added in 2025. Scilex Bio Reports Positive Results from the Recently Completed Phase 1 Trials Conducted by NeuroBiogen for KDS2010, a Novel Oral Tablet Recently Synthesized Potent, Selective, and Reversible Monoamine Oxidase B inhibitor

Scilex Holding Company Announces Receipt of Notice from Nasdaq

Nov 22, 2024, 6:00 AM EST - 1 year ago

Scilex Holding Company Announces Receipt of Notice from Nasdaq

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Announces Today the Filing of a Registration Statement on Form S-4 by Denali Capital Acquisition Corp. with the Securities and Exchange Commission Relating to the Previously Announced Proposed Business Combination Between Semnur and Denali

Nov 6, 2024, 12:24 PM EST - 1 year ago

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Announces Today the Filing of a Registration Statement on Form S-4 by Denali Capital Acquisition Corp. with the Securities and Exchange Commission Relating to the Previously Announced Proposed Business Combination Between Semnur and Denali

Scilex Pharmaceuticals Inc, a Wholly Owned Subsidiary of Scilex Holding Company, Announces Successful End of Phase II Meeting with FDA Leading to an Agreed Path Forward to NDA Upon Completion of Phase III Trials for Blockbuster Product Candidate, SP-103 (Lidocaine Topical System) 5.4%, a Next-Generation, Triple-Strength Formulation of ZTlido, for the Treatment of Chronic Neck Pain Associated with Muscle Spasms

Oct 30, 2024, 6:00 AM EDT - 1 year ago

Scilex Pharmaceuticals Inc, a Wholly Owned Subsidiary of Scilex Holding Company, Announces Successful End of Phase II Meeting with FDA Leading to an Agreed Path Forward to NDA Upon Completion of Phase III Trials for Blockbuster Product Candidate, SP-103 (Lidocaine Topical System) 5.4%, a Next-Generation, Triple-Strength Formulation of ZTlido, for the Treatment of Chronic Neck Pain Associated with Muscle Spasms

Scilex Holding Company, Following its Prior Announcement of the Record Date for a Dividend of Preferred Stock, Reiterates Information Previously Provided to Scilex Stockholders Regarding Manipulative and Naked Short Selling of Scilex Common Stock

Oct 29, 2024, 6:00 AM EDT - 1 year ago

Scilex Holding Company, Following its Prior Announcement of the Record Date for a Dividend of Preferred Stock, Reiterates Information Previously Provided to Scilex Stockholders Regarding Manipulative and Naked Short Selling of Scilex Common Stock

Scilex Holding Company sets November 7, 2024 as the Record Date for a Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary

Oct 28, 2024, 6:00 AM EDT - 1 year ago

Scilex Holding Company sets November 7, 2024 as the Record Date for a Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Provides Timing to File in October 2024 a Registration Statement on Form S-4 with the SEC relating to the Previously Announced Proposed Business Combination Between Semnur and Denali with a Pre-Transaction Equity Value of $2.5 Billion

Oct 16, 2024, 4:00 AM EDT - 1 year ago

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Provides Timing to File in October 2024 a Registration Statement on Form S-4 with the SEC relating to the Previously Announced Proposed Business Combination Between Semnur and Denali with a Pre-Transaction Equity Value of $2.5 Billion

Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for the Quarter Ended September 30, 2024

Oct 8, 2024, 1:58 PM EDT - 1 year ago

Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for the Quarter Ended September 30, 2024

Scilex Holding Company Announces Closing of a $50 Million Registered Convertible Financing

Oct 8, 2024, 11:50 AM EDT - 1 year ago

Scilex Holding Company Announces Closing of a $50 Million Registered Convertible Financing

Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt

Oct 7, 2024, 10:00 AM EDT - 1 year ago

Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt

ORMP

Scilex Holding Company Announces Signing of a $50 Million Registered Convertible Financing to Refinance and Restructure Existing Debt & Further Strengthens Financial Profile

Oct 7, 2024, 9:52 AM EDT - 1 year ago

Scilex Holding Company Announces Signing of a $50 Million Registered Convertible Financing to Refinance and Restructure Existing Debt & Further Strengthens Financial Profile

Top 3 Health Care Stocks That Could Blast Off In September

Sep 10, 2024, 7:27 AM EDT - 1 year ago

Top 3 Health Care Stocks That Could Blast Off In September

AMN PDCO

KimCoyneFactoryPR
KimCoyneFactoryPR Nov. 15 at 12:27 AM
$SCLX here are the key takeaways from the 3rd Quarter 2025 10-Q: - Less than $1M in cash available - $213M in rebate liabilities (these have to be paid) -$67M in outstanding AP (this is owed to vendors and third parties) - YTD sales revenue down 40% YoY (down 27% in Q3 vs prior Q3) - $258M loss in Q3. A quarter of a billion dollars How do you pay off $213M in rebate liabilities with less than $1M in cash? Explain it, and if you can I will invest in this company.
0 · Reply
GlobalMarketBulletin
GlobalMarketBulletin Nov. 14 at 11:36 PM
$SCLX Scilex Holding Company shares surged 26% in the past month after heavy sell-offs earlier in 2025. Despite the rebound, SCLX remains down 30% year-over-year as investors weigh its declining 13% revenue, 2.5× P/S ratio, and future in non-opioid pain therapy. https://globalmarketbulletin.com/scilex-sclx-jumps-26-in-30-days-but-still-down-30-yoy-is-the-rally-sustainable/
0 · Reply
KingStocks1
KingStocks1 Nov. 14 at 11:18 PM
$SCLX 1 mill comprehensive loss last year this quarter vs this year showing 260 million loss for the quarter ending September 2025??? What the fk!?
0 · Reply
Excitingshorts
Excitingshorts Nov. 14 at 11:04 PM
$SCLX 2025 is the last year of being in the red. Well be positive next quarter due to increased global revenue. Not easy for any biotech to say that
1 · Reply
d_risk
d_risk Nov. 14 at 10:58 PM
$SCLX - Scilex Holding Company Common Stock - 10Q - Updated Risk Factors SCLX’s latest 10-Q flags updated financials, debt, and supplier risks, plus a major new focus on crypto: regulatory uncertainty, market swings, cybersecurity threats, and accounting challenges now loom large. #Pharmaceuticals #Cybersecurity #FinancialRisk #RegulatoryRisk #Cryptocurrency 🟢 Added 🟠 Removed https://d-risk.ai/SCLX/10-Q/2025-11-14
0 · Reply
BioCEOsSukk
BioCEOsSukk Nov. 14 at 10:47 PM
$SCLX $DVLT $SRNE https://ir.geniusgroup.net/news-events/press-releases/detail/214/genius-group-files-federal-securities-class-action-lawsuit
0 · Reply
Rookie69
Rookie69 Nov. 14 at 10:35 PM
$SCLX think the village idiot will ask AI to expain another 40% drop in sales or keep fapping to Kimmys bullshit along with DJ this 10-Q may take the prize as worst Henry performance to date
0 · Reply
BioCEOsSukk
BioCEOsSukk Nov. 14 at 10:26 PM
$SCLX holy filings, Batman. Scilex getting their filings in order for something? 😁😁😁
0 · Reply
Sacsofcash
Sacsofcash Nov. 14 at 8:18 PM
$SCLX KimCoyneFactoryPR 👇👇👇👇👇👇👇
2 · Reply
Argentum99
Argentum99 Nov. 14 at 6:59 PM
$SCLX done. I vote against. Ji, $SCLX SP102 SEMDEXA, in commercial phase, when?? and $SRNE chapter 11 definitions, when??
0 · Reply
TheToaster
TheToaster Nov. 14 at 6:27 PM
$SCLX its because shareholders suffer that they do well. Without products that generate a profit, shareholders will never do well. W a management that pays themselves like theyre fortune 500, shareholders will never do well. Management knows this and the product they sell is hope and shares. Not just tonpay their salary but the probably borrow back some of those shares to ahort them at the pumps.
0 · Reply
Sacsofcash
Sacsofcash Nov. 14 at 6:21 PM
$SCLX fake /mposter basement dweller Pig.
1 · Reply
Sacsofcash
Sacsofcash Nov. 14 at 6:15 PM
$SCLX
0 · Reply
HostmanG
HostmanG Nov. 14 at 5:49 PM
$SCLX OPTIONS REPRICING?? I voted against the Option Repricing. Am wondering if the LONGS here did the same? It doesn't seem fair the people at SCLX who helped kill our stock price don't have to suffer the same consequences as the retail common shareholders. Maybe I'm misunderstanding the Repricing language??
0 · Reply
BioCEOsSukk
BioCEOsSukk Nov. 14 at 4:49 PM
$SCLX the context the troll is using is all wrong. I saw the whole post and if tokenization is only the future, that doesn't mean Scilex and $SRNE aren't addressing the present too. I've seen what the LT is up to and I have an inkling what Scilex is up to as well. And if I'm right, shorts will be screwed and longs brokerages will be massively renewed... IMO
0 · Reply
KimCoyneFactoryPR
KimCoyneFactoryPR Nov. 14 at 4:27 PM
$SCLX this guy had to un-retire because he lost all of his money in Sorrento and Sciled. He had to pack up his dream retirement home and go back to litigating botched circumcision cases. His wife had her dreams snatched because this degenerate leveraged their future. I may be a troll, but I didn’t ruin my family like you did. If I did what you did and I would have the common courtesy to make my life insurance available so my wife could continue on without my mistakes holding her down.
0 · Reply
TopAdvance
TopAdvance Nov. 14 at 4:08 PM
$SCLX This is the biggest troll operating in anonymity with such cowardice and absolute deception that nobody believes a word you type with your troll-like thumbs. Kim is an amazing person and the jealousy oozes from your zit-ridden pores. Don’t you have anything better to do?
2 · Reply
Sacsofcash
Sacsofcash Nov. 14 at 1:23 PM
$SCLX Datavault AI to Announce Third Quarter 2025 Financial Highlights and Corporate Update on Monday, Nov. 17, 2025https://ir.datavaultsite.com/news-events/press-releases/detail/387/datavault-ai-to-announce-third-quarter-2025-financial
1 · Reply
Skunky
Skunky Nov. 14 at 12:45 PM
$SCLX $DVLT BTC is under 95K
0 · Reply
Skunky
Skunky Nov. 14 at 11:57 AM
$SCLX Amazing timing . BTC is now breaking down. $DVLT
0 · Reply
Skunky
Skunky Nov. 14 at 11:45 AM
$SCLX $DVLT Bitcoin broke below $96K
0 · Reply
Skunky
Skunky Nov. 14 at 10:47 AM
$SCLX $DVLT Bitcoin 97K
0 · Reply